Interpretable Clinical Genomics with a Likelihood Ratio Paradigm.
暂无分享,去创建一个
Damian Smedley | Julius O. B. Jacobsen | Xingmin Aaron Zhang | Melissa A. Haendel | Manuel Holtgrewe | Vida Ravanmehr | Daniel Danis | Justin Reese | Julius O.B. Jacobsen | Peter N. Robinson | Michael A. Gargano | Michael Gargano | Leigh C. Carmody | Courtney Thaxton | Sebastian Koehler | Julie A. McMurry | Peter N. Robinson | Guy Karlebach | D. Smedley | P. Robinson | M. Holtgrewe | M. Haendel | J. Reese | L. Carmody | D. Danis | J. McMurry | Sebastian Koehler | C. Thaxton | V. Ravanmehr | G. Karlebach | X. A. Zhang | M. Gargano
[1] Clara Gaff,et al. Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions , 2017, JAMA pediatrics.
[2] D. Goldstein,et al. Genic Intolerance to Functional Variation and the Interpretation of Personal Genomes , 2013, PLoS genetics.
[3] Bart De Moor,et al. eXtasy: variant prioritization by genomic data fusion , 2013, Nature Methods.
[4] Laurie D. Smith,et al. A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases , 2015, Genome Medicine.
[5] Sabine Van Huffel,et al. Interval Coded Scoring: a toolbox for interpretable scoring systems , 2018, PeerJ Comput. Sci..
[6] Alexander A. Morgan,et al. Likelihood ratios for genome medicine , 2010, Genome Medicine.
[7] Lin Yang,et al. PhenoPro: a novel toolkit for assisting in the diagnosis of Mendelian disease , 2019, Bioinform..
[8] Cynthia Rudin,et al. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead , 2018, Nature Machine Intelligence.
[9] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[10] Tudor Groza,et al. The Human Phenotype Ontology in 2017 , 2016, Nucleic Acids Res..
[11] Damian Smedley,et al. Next-generation diagnostics and disease-gene discovery with the Exomiser , 2015, Nature Protocols.
[12] Daniele Merico,et al. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test , 2017, Genetics in Medicine.
[13] B. Fernandez,et al. Utility of whole‐exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care , 2015, Clinical genetics.
[14] Carsten Bergmann,et al. Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia. , 2008, American journal of human genetics.
[15] P. Robinson,et al. The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. , 2008, American journal of human genetics.
[16] Chunlei Liu,et al. ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..
[17] A. Albert,et al. On the use and computation of likelihood ratios in clinical chemistry. , 1982, Clinical chemistry.
[18] A. Olry,et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database , 2019, European Journal of Human Genetics.
[19] David R. FitzPatrick,et al. Paediatric genomics: diagnosing rare disease in children , 2018, Nature Reviews Genetics.
[20] Tetsuya Okazaki,et al. Comparison of Causative Variant Prioritization Tools Using Next-generation Sequencing Data in Japanese Patients with Mendelian Disorders. , 2019, Yonago acta medica.
[21] Damian Smedley,et al. Effective diagnosis of genetic disease by computational phenotype analysis of the disease-associated genome , 2014, Science Translational Medicine.
[22] Feller William,et al. An Introduction To Probability Theory And Its Applications , 1950 .
[23] P. Ng,et al. Phen-Gen: combining phenotype and genotype to analyze rare disorders , 2014, Nature Methods.
[24] Tsviya Olender,et al. VarElect: the phenotype-based variation prioritizer of the GeneCards Suite , 2016, BMC Genomics.
[25] P. Robinson,et al. Marfan syndrome: an update of genetics, medical and surgical management , 2007, Heart.
[26] S. Mundlos,et al. The Human Phenotype Ontology , 2010, Clinical genetics.
[27] Patrice Godard,et al. PCAN: phenotype consensus analysis to support disease-gene association , 2016, BMC Bioinformatics.
[28] Anna Lehman,et al. The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study , 2018, Genetics in Medicine.
[29] S. Blankenberg,et al. Dural ectasia in Loeys–Dietz syndrome: comprehensive study of 30 patients with a TGFBR1 or TGFBR2 mutation , 2014, Clinical genetics.
[30] Isaac S Kohane,et al. Artificial Intelligence in Healthcare , 2019, Artificial Intelligence and Machine Learning for Business for Non-Engineers.
[31] Kenneth F Schulz,et al. Refining clinical diagnosis with likelihood ratios , 2005, The Lancet.
[32] Damian Smedley,et al. Improved exome prioritization of disease genes through cross-species phenotype comparison , 2014, Genome research.
[33] Hui Yang,et al. Phenolyzer: phenotype-based prioritization of candidate genes for human diseases , 2015, Nature Methods.
[34] Damian Smedley,et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data , 2014, Nucleic Acids Res..
[35] Tudor Groza,et al. Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources , 2018, Nucleic Acids Res..
[36] Carmela Bravaccio,et al. Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough? , 2018, Italian Journal of Pediatrics.
[37] Marcel H. Schulz,et al. Clinical diagnostics in human genetics with semantic similarity searches in ontologies. , 2009, American journal of human genetics.
[38] R. Srinivasan,et al. Phenotype-driven gene prioritization for rare diseases using graph convolution on heterogeneous networks , 2018, BMC Medical Genomics.
[39] Murat Sincan,et al. Detecting false‐positive signals in exome sequencing , 2012, Human mutation.
[40] Peter N. Robinson,et al. Phenotype-driven strategies for exome prioritization of human Mendelian disease genes , 2015, Genome Medicine.
[41] M Super,et al. A clinical study of type 1 neurofibromatosis in north west England , 1999, Journal of medical genetics.
[42] J. Kassirer,et al. Therapeutic decision making: a cost-benefit analysis. , 1975, The New England journal of medicine.
[43] Daniel R. Richards,et al. Leveraging network analytics to infer patient syndrome and identify causal genes in rare disease cases , 2017, BMC Genomics.
[44] D. Altman,et al. Diagnostic tests 4: likelihood ratios , 2004, BMJ : British Medical Journal.
[45] Brett J. Kennedy,et al. Phevor combines multiple biomedical ontologies for accurate identification of disease-causing alleles in single individuals and small nuclear families. , 2014, American journal of human genetics.
[46] Matthew N. Bainbridge,et al. A visual and curatorial approach to clinical variant prioritization and disease gene discovery in genome-wide diagnostics , 2016, Genome Medicine.
[47] Peter N. Robinson,et al. Introduction to Bio-Ontologies , 2011 .
[48] Rosario M. Piro,et al. Computational Exome and Genome Analysis , 2017 .
[49] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[50] Desheng Liang,et al. Three Novel Mutations in FBN1 and TGFBR2 in Patients with the Syndromic Form of Thoracic Aortic Aneurysms and Dissections. , 2018, International heart journal.
[51] Deborah Nickerson,et al. Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L. , 2016, American journal of human genetics.